Newron Pharmaceuticals S.p.A.

NWRN

Equity

ISIN IT0004147952 / Valor 2791431

SIX Swiss Exchange (2026-07-06)

CHF 14.95-4.39%

Newron Pharmaceuticals S.p.A.
UMushroom community rating:

4.50 4 votes No rating yet

NegativeNeutralPositive

About company

Newron Pharmaceuticals S.p.A., established in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, New Jersey, is a biopharmaceutical company specializing in the development of innovative therapies for central and peripheral nervous system disorders. The company aims to expand its product portfolio through both internal research and development and strategic licensing and acquisition of novel compounds targeting the central nervous system (CNS) at various stages of development. Newron's shares are publicly traded on the SIX Swiss Exchange under the ticker symbol NWRN, as well as on the primary market of the Düsseldorf Stock Exchange and XETRA under the trading symbol NP5.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

74.0%1Y

105%3Y

378%5Y

Performance

58.7%1Y

68.3%3Y

73.9%5Y

Volatility

303 M

Market cap (USD)

67,225

Daily traded volume (Shares)

8.99 / 8.39

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.50

4 votes

Performance:

3.25

Innovation:

4.50

Society:

4.50

Nature:

3.75

Uwe K.

Switzerland, 30 Mar 2025

Könnte interessant sein.

Caterina F

Switzerland, 26 Mar 2025

Worth paying attention to

Markus Fässler

Switzerland, 05 Feb 2024

Evenamide, Newron’s innovative drug to treat schizophrenia, has proven safe and effective in use for TRS patients.

EQUITIES OF THE SAME SECTOR

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc Valor: 22860122

Annual Return

-50%0%+50%

Risk level

110

3.37%USD 33.47

Pacira BioSciences Inc

Pacira BioSciences Inc Valor: 12338490

Annual Return

-50%0%+50%

Risk level

110

1.44%USD 25.39

Boston Scientific Corp

Boston Scientific Corp Valor: 913577

Annual Return

-50%0%+50%

Risk level

110

4.83%USD 45.14

Teladoc Health Inc

Teladoc Health Inc Valor: 28438140

Annual Return

-50%0%+50%

Risk level

110

1.10%USD 9.20

Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc Valor: 25337263

Annual Return

-50%0%+50%

Risk level

110

3.41%USD 114.17

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc Valor: 24511852

Annual Return

-50%0%+50%

Risk level

110

-2.29%USD 19.64

The Platform Group AG

The Platform Group AG Valor: 57796644

Annual Return

-50%0%+50%

Risk level

110

1.69%EUR 0.96

Unitedhealth Group Inc

Unitedhealth Group Inc Valor: 1078451

Annual Return

-50%0%+50%

Risk level

110

-0.28%USD 425.36

Encompass Health Corporation

Encompass Health Corporation Valor: 39085960

Annual Return

-50%0%+50%

Risk level

110

5.00%USD 106.46

Tenet Healthcare Corp

Tenet Healthcare Corp Valor: 19722583

Annual Return

-50%0%+50%

Risk level

110

6.55%USD 203.72

Logos provided by Clearbit

Newron Pharmaceuticals S.p.A.

NWRN

ISIN IT0004147952 / Valor 2791431

Newron Pharmaceuticals S.p.A. UMushroom community rating:

Uwe K.

Caterina F

Markus Fässler

Newron Pharmaceuticals S.p.A.
UMushroom community rating: